Financial Architects (New Jersey)’s CRISPR Therapeutics CRSP Stock Holding History

Financial Architects (New Jersey)’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,005	Closed	-$307K	–	332
2020 Q4	$307K	Buy	+2,005	New	+$237K	0.06%	220
2020 Q3	–	Sell	-181	Closed	-$13K	–	371
2020 Q2	$13K	Hold	181	–	–	﹤0.01%	610
2020 Q1	$8K	Buy	+181	New	+$9.35K	﹤0.01%	651
2019 Q1	–	Sell	-300	Closed	-$9K	–	1431
2018 Q4	$9K	Buy	+300	New	+$10.4K	﹤0.01%	1010
2018 Q2	–	Sell	-1,000	Closed	-$46K	–	1357
2018 Q1	$46K	Buy	+1,000	New	+$41.3K	0.01%	630

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Financial Architects (New Jersey)'s CRSP Position: Q1 2021 in Review

Financial Architects (New Jersey) sold out of CRISPR Therapeutics (CRSP) in Q1 2021, closing a stake of 2,005 shares — an estimated $307K sold.

Financial Architects (New Jersey) first reported a position in CRSP in Q1 2018 and held it in 5 quarters. The position peaked at $307K in Q4 2020. 443 funds tracked by Wall St. Rank hold CRSP as of Q1 2021.

Financial Architects (New Jersey) reported no remaining CRISPR Therapeutics position as of Q1 2021 after selling out during the quarter.
Financial Architects (New Jersey) sold 2,005 CRISPR Therapeutics shares in Q1 2021, an estimated $307K.
Financial Architects (New Jersey) first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 5 quarters.
Financial Architects (New Jersey)'s CRISPR Therapeutics position peaked at $307K in Q4 2020.
443 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2021.

Based on Financial Architects (New Jersey)'s 13F filing for Q1 2021, filed 17 May 2021.